Total Payments
$26,008
2024 Payments
$365.91
Companies
7
Transactions
34
Medicare Patients
128
Medicare Billing
$20,591
Payment Breakdown by Category
Consulting$17,543 (67.5%)
Research$4,270 (16.4%)
Other$3,054 (11.7%)
Travel$933.08 (3.6%)
Food & Beverage$208.95 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $17,543 | 8 | 67.5% |
| Unspecified | $4,270 | 7 | 16.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,054 | 4 | 11.7% |
| Travel and Lodging | $933.08 | 7 | 3.6% |
| Food and Beverage | $208.95 | 8 | 0.8% |
Payments by Type
General
$21,738
27 transactions
Research
$4,270
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $7,302 | 9 | $0 (2020) |
| Janssen Scientific Affairs, LLC | $7,223 | 4 | $0 (2022) |
| F. Hoffmann-La Roche AG | $4,783 | 8 | $0 (2024) |
| Janssen Global Services, LLC | $3,710 | 2 | $0 (2021) |
| Novartis Pharmaceuticals Corporation | $1,541 | 2 | $0 (2020) |
| Ventana Medical Systems, Inc. | $1,411 | 8 | $0 (2017) |
| Genentech, Inc. | $39.26 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $365.91 | 1 | F. Hoffmann-La Roche AG ($365.91) |
| 2022 | $4,989 | 4 | Janssen Scientific Affairs, LLC ($4,950) |
| 2021 | $5,749 | 4 | Janssen Scientific Affairs, LLC ($2,273) |
| 2020 | $4,313 | 4 | Janssen Research & Development, LLC ($1,860) |
| 2019 | $2,991 | 4 | Janssen Global Services, LLC ($1,550) |
| 2018 | $1,244 | 6 | F. Hoffmann-La Roche AG ($638.60) |
| 2017 | $6,357 | 11 | Janssen Research & Development, LLC ($4,946) |
All Payment Transactions
34 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/30/2024 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $365.91 | Research |
| Study: LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC • Category: BioOncology | ||||||
| 09/21/2022 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 06/07/2022 | Genentech, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $39.26 | General |
| Category: BioOncology | ||||||
| 04/14/2022 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 04/14/2022 | Janssen Scientific Affairs, LLC | RYBREVANT (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: Oncology | ||||||
| 12/14/2021 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $2,272.50 | General |
| 05/05/2021 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $2,160.00 | General |
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $749.32 | Research |
| Study: A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC • Category: BioOncology | ||||||
| 03/31/2021 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | — | In-kind items and services | $566.81 | Research |
| Study: A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $569.74 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 12/31/2020 | F. Hoffmann-La Roche AG | Tecentriq (Biological) | — | In-kind items and services | $477.06 | Research |
| Study: LCMC3 • Category: BioOncology | ||||||
| 11/19/2020 | Novartis Pharmaceuticals Corporation | — | — | In-kind items and services | $1,406.00 | Research |
| Study: RESEARCH RELATED PUBLICATIONS SUPPORT | ||||||
| 04/30/2020 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| 09/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $714.78 | General |
| Category: BioOncology | ||||||
| 06/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $700.31 | General |
| Category: BioOncology | ||||||
| 05/31/2019 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $26.00 | General |
| 04/23/2019 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,550.00 | General |
| 06/30/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $638.60 | General |
| Category: BioOncology | ||||||
| 02/13/2018 | Novartis Pharmaceuticals Corporation | NIR178X (Drug) | — | In-kind items and services | $134.82 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT | ||||||
| 01/04/2018 | Janssen Research & Development, LLC | — | Travel and Lodging | Cash or cash equivalent | $363.89 | General |
| 01/04/2018 | Janssen Research & Development, LLC | — | Food and Beverage | Cash or cash equivalent | $54.55 | General |
| 01/04/2018 | Janssen Research & Development, LLC | — | Food and Beverage | In-kind items and services | $46.37 | General |
| 01/04/2018 | Janssen Research & Development, LLC | — | Food and Beverage | Cash or cash equivalent | $5.30 | General |
| 12/20/2017 | Janssen Research & Development, LLC | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 12/20/2017 | Janssen Research & Development, LLC | — | Travel and Lodging | In-kind items and services | $170.53 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $1,406 | 1 |
| A PHASE II, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB AS NEOADJUVANT AND ADJUVANT THERAPY IN PATIENTS WITH STAGE IB, II, IIIA RESECTABLE AND UNTREATED NON-SMALL CELL LUNG CANCER NSCLC | F. Hoffmann-La Roche AG | $1,316 | 2 |
| LCMC3 | F. Hoffmann-La Roche AG | $1,047 | 2 |
| LCMC3: Long-Term Disease-Free and Overall Survival and Their Association With ctDNA After Neoadjuvant Atezolizumab for NSCLC | F. Hoffmann-La Roche AG | $365.91 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | Novartis Pharmaceuticals Corporation | $134.82 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 17 | 32 | $5,705 | $2,518 |
| 2022 | 2 | 24 | 41 | $6,044 | $2,756 |
| 2021 | 2 | 29 | 67 | $12,853 | $6,827 |
| 2020 | 3 | 58 | 110 | $20,593 | $8,490 |
Total Patients
128
Total Services
250
Medicare Billing
$20,591
Procedure Codes
8
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 17 | 32 | $5,705 | $2,518 | 44.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 13 | 24 | $4,032 | $1,891 | 46.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 11 | 17 | $2,012 | $865.32 | 43.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 41 | $8,845 | $4,803 | 54.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 14 | 26 | $4,008 | $2,025 | 50.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 74 | $15,910 | $6,550 | 41.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 15 | 21 | $3,213 | $1,301 | 40.5% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 12 | 15 | $1,470 | $639.50 | 43.5% |
About Dr. Eric Haura, MD
Dr. Eric Haura, MD is a Internal Medicine healthcare provider based in Tampa, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1801829007.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Eric Haura, MD has received a total of $26,008 in payments from pharmaceutical and medical device companies, with $365.91 received in 2024. These payments were reported across 34 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($17,543).
As a Medicare-enrolled provider, Haura has provided services to 128 Medicare beneficiaries, totaling 250 services with total Medicare billing of $20,591. Data is available for 4 years (2020–2023), covering 8 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology
- Location Tampa, FL
- Active Since 07/09/2006
- Last Updated 02/11/2008
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1801829007
Products in Payments
- RYBREVANT (Drug) $4,950
- TECENTRIQ (Biological) $3,409
- Tecentriq (Biological) $1,413
- VENTANA RESEARCH & DEVELOPMENT (Device) $1,411
- NIR178X (Drug) $134.82
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tampa
Javier Pinilla-Ibarz, Md, MD
Internal Medicine — Payments: $1.9M
Internal Medicine $1.9M
Alberto Chiappori, Md, MD
Internal Medicine — Payments: $617,120
Internal Medicine $617,120
Ricardo Restrepo-Jaramillo, M.d, M.D
Internal Medicine — Payments: $562,511
Internal Medicine $562,511
Dr. Sady Alpizar, Md, MD
Internal Medicine — Payments: $509,824
Internal Medicine $509,824
Jhanelle Gray, Md, MD
Internal Medicine — Payments: $273,892
Internal Medicine $273,892
Dr. Andrew Kuykendall, M.d, M.D
Internal Medicine — Payments: $273,357
Internal Medicine $273,357